Health

Source link : https://newshealth.biz/health-news/impella-flops-for-acute-coronary-syndrome-patients-not-in-shock/ NEW ORLEANS — Microaxial flow pump circulatory support with the Impella device during percutaneous coronary intervention (PCI) didn’t help outcomes for complex patients not in cardiogenic shock, two randomized trials at the American College of Cardiology (ACC) annual meeting showed. In an elective and largely stable but high-risk population in the CHIP-BCIS3 trial, Bayesian win […] […] More

Source link : https://newshealth.biz/health-news/lower-really-is-better-for-secondary-prevention-cholesterol-targets/ NEW ORLEANS — The more intensive LDL cholesterol target guidelines recommended for secondary prevention in high-risk patients with atherosclerotic cardiovascular (CV) disease improved outcomes in a randomized trial from South Korea. Compared with the LDL cholesterol target of less than 70 mg/dL typical for lower risk and primary prevention patients, targeting less than 55 mg/dL […] […] More

Source link : https://newshealth.biz/health-news/who-would-do-something-so-stupid-what-we-heard-this-week/ “Conceptually, you might think, ‘Who would do something so stupid?’” — Elliot Fishman, MD, of Johns Hopkins Medicine in Baltimore, discussing the malicious potential of deepfake X-rays. “Sadly, younger physicians are about to be re-educated about what these diseases look like.” — Paul Offit, MD, of the Children’s Hospital of Philadelphia, on the resurgence of […] […] More

Source link : https://newshealth.biz/health-news/high-dx-yield-supports-workup-for-inoca/ Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%. Medscape Medical News Source link : https://www.medscape.com/viewarticle/comprehensive-workup-yields-diagnosis-most-nonobstructive-2026a10009je?src=rss Author : Publish date : 2026-03-29 19:23:00 Copyright for syndicated content belongs to the linked Source. The post High Dx Yield Supports Workup for INOCA first […] More

Source link : https://newshealth.biz/health-news/resistant-dermatomyositis-improves-quickly-significantly-with-combination-drug/ DENVER — Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial. The higher of two doses of brepocitinib improved the total dermatomyositis score by almost 50% at 1 year as compared with placebo. The novel therapy demonstrated superiority over placebo across all nine secondary endpoints, including skin disease, glucocorticoid […] […] More

Source link : https://newshealth.biz/health-news/pcks9s-seen-driving-down-ldl-c-in-diabetes/ A subgroup analysis of the VASALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis. Medscape Medical News Source link : https://www.medscape.com/viewarticle/pcks9s-seen-driving-down-ldl-c-diabetes-2026a10009jb?src=rss Author : Publish date : 2026-03-29 18:16:00 Copyright for syndicated content belongs to the linked Source. The post PCKS9s Seen Driving Down LDL-C in […] More

Source link : https://newshealth.biz/health-news/upadacitinib-significantly-improves-vitiligo-vs-placebo/ The JAK1 inhibitor in development for treating nonsegmental vitiligo was superior to placebo on investigator ratings in two phase 3 trials. Medscape Medical News Source link : https://www.medscape.com/viewarticle/upadacitinib-results-significant-improvements-nonsegmental-2026a10009j2?src=rss Author : Publish date : 2026-03-29 17:23:00 Copyright for syndicated content belongs to the linked Source. The post Upadacitinib Significantly Improves Vitiligo vs Placebo first appeared on News […] More

Source link : https://newshealth.biz/health-news/dermatomyositis-targeted-drug-shows-promise-vs-placebo/ At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments. Medscape Medical News Source link : https://www.medscape.com/viewarticle/dermatomyositis-targeted-drug-shows-promise-vs-placebo-2026a10009iz?src=rss Author : Publish date : 2026-03-29 16:39:00 Copyright for syndicated content belongs to the linked Source. The post Dermatomyositis: Targeted Drug Shows Promise vs […] More

Source link : https://newshealth.biz/health-news/my-patients-are-asking-for-leucovorin-heres-what-i-tell-them/ When the White House announced it was exploring leucovorin as a treatment for autism, the calls from families started pouring in: “Can you prescribe leucovorin for my child?” We experience versions of this frequently: an unproven treatment gains momentum on social media, and we as physicians must become informed enough to counsel families who are […] […] More

Source link : https://newshealth.biz/health-news/active-surveillance-for-dcis-moves-closer-to-standard-option-but-not-quite-there/ Women who opted for active surveillance (AS) for ductal carcinoma in situ (DCIS) had ipsilateral invasive breast cancer survival (iiBCS) similar to patients who had immediate surgery, a randomized trial showed. After a total follow-up of about 4 years, iiBCS favored AS at 24 months (94.3% vs 90.6%) and met statistical criteria for non-inferiority at […] […] More

Source link : https://newshealth.biz/health-news/complement-inhibitor-slowed-kidney-decline-in-iga-nephropathy/ Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued approval was contingent on demonstrating slowed kidney decline. Fewer participants in the iptacopan group reached the composite kidney-failure endpoint. Iptacopan (Fabhalta) slowed kidney function decline in adults with […] […] More

Source link : https://newshealth.biz/health-news/hi-peitho-kicks-off-golden-era-in-pulmonary-embolism/ NEW ORLEANS — A major advance for the treatment of intermediate-risk pulmonary embolism (PE) arrived with HI-PEITHO’s landmark report on ultrasound-facilitated, catheter-directed thrombolysis (CDT). In this hard-to-treat group of acute PE patients, the composite endpoint of PE-related death, cardiorespiratory decompensation or collapse, or symptomatic recurrence of PE within 7 days significantly favored individuals who got […] […] More